Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur J. Robert CADE |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
?-Casomorphin Induces Fos-Like Immunoreactivity in Discrete Brain Regions Relevant to Schizophrenia and Autism / Zhongjie SUN in Autism, 3-1 (March 1999)
[article]
Titre : ?-Casomorphin Induces Fos-Like Immunoreactivity in Discrete Brain Regions Relevant to Schizophrenia and Autism Type de document : Texte imprimé et/ou numérique Auteurs : Zhongjie SUN, Auteur ; J. Robert CADE, Auteur ; Melvin J. FREGLY, Auteur ; R. Malcolm PRIVETTE, Auteur Article en page(s) : p.67-83 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The induction of Fos-like immunoreactivity (FLI) was used to determine the brain localization affected by b-casomorphin-7 (b-CM7). Peripheral administration of human b-CM7 at different doses (5, 10 and 30 mg/kg, IV for 1 hour) to rats induced moderate to strong FLI in discrete brain regions including the nucleus accumbens, caudate putamen, ventral tegmental and median raphe nucleus, and orbitofrontal, prefrontal, parietal, temporal, occipital and entorhinal cortex. All of the above areas have been shown to be altered either functionally or anatomically in patients with schizophrenia, and most have been shown to be functionally abnormal in autism. Some of these brain areas are originators or components of dopaminergic, serotoninergic and GABA-ergic pathways, suggesting that b-CM7 can affect the function of all of these systems. The role of some other affected areas in emotional and motivated behavior, social adaptation, hallucinations and delusions suggests that b-CM7, which was found in high concentration in the CSF, blood and urine of patients with either schizophrenia or autism, may be relevant to schizophrenia and autism. Induction of FLI in the above brain areas by a moderate dose (10 mg/kg) of b-CM7 was attenuated significantly, or blocked, by pretreatment with naloxone (2 mg/kg, IP). It is concluded that human b-CM7 can cross the blood-brain barrier, activate opioid receptors and affect brain regions similar to those affected by schizophrenia and autism. En ligne : http://dx.doi.org/10.1177/1362361399003001006 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=208
in Autism > 3-1 (March 1999) . - p.67-83[article] ?-Casomorphin Induces Fos-Like Immunoreactivity in Discrete Brain Regions Relevant to Schizophrenia and Autism [Texte imprimé et/ou numérique] / Zhongjie SUN, Auteur ; J. Robert CADE, Auteur ; Melvin J. FREGLY, Auteur ; R. Malcolm PRIVETTE, Auteur . - p.67-83.
Langues : Anglais (eng)
in Autism > 3-1 (March 1999) . - p.67-83
Index. décimale : PER Périodiques Résumé : The induction of Fos-like immunoreactivity (FLI) was used to determine the brain localization affected by b-casomorphin-7 (b-CM7). Peripheral administration of human b-CM7 at different doses (5, 10 and 30 mg/kg, IV for 1 hour) to rats induced moderate to strong FLI in discrete brain regions including the nucleus accumbens, caudate putamen, ventral tegmental and median raphe nucleus, and orbitofrontal, prefrontal, parietal, temporal, occipital and entorhinal cortex. All of the above areas have been shown to be altered either functionally or anatomically in patients with schizophrenia, and most have been shown to be functionally abnormal in autism. Some of these brain areas are originators or components of dopaminergic, serotoninergic and GABA-ergic pathways, suggesting that b-CM7 can affect the function of all of these systems. The role of some other affected areas in emotional and motivated behavior, social adaptation, hallucinations and delusions suggests that b-CM7, which was found in high concentration in the CSF, blood and urine of patients with either schizophrenia or autism, may be relevant to schizophrenia and autism. Induction of FLI in the above brain areas by a moderate dose (10 mg/kg) of b-CM7 was attenuated significantly, or blocked, by pretreatment with naloxone (2 mg/kg, IP). It is concluded that human b-CM7 can cross the blood-brain barrier, activate opioid receptors and affect brain regions similar to those affected by schizophrenia and autism. En ligne : http://dx.doi.org/10.1177/1362361399003001006 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=208 A Peptide Found in Schizophrenia and Autism Causes Behavioral Changes in Rats / Zhongjie SUN in Autism, 3-1 (March 1999)
[article]
Titre : A Peptide Found in Schizophrenia and Autism Causes Behavioral Changes in Rats Type de document : Texte imprimé et/ou numérique Auteurs : Zhongjie SUN, Auteur ; J. Robert CADE, Auteur Article en page(s) : p.85-95 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : In a previous study we showed that ?-casomorphin-7 (?-CM7) is taken up by brain regions relevant to schizophrenia and autism. The present experiment was designed to find whether ?-CM7 has any behavioral or analgesic effects in rats. About 65 seconds after treatment with different doses of ?-CM7, rats became restless and ran violently, with teeth chattering and with rapid respiration. Seven minutes later, the rats became inactive with less walking, distancing themselves from the other rat in the same cage, and sitting in, or putting their head against, the corner of the cage. The sound response was reduced and social interaction was absent. One hour later, the rats showed hyperdefensiveness. The above behavioral effects of ?-CM7 did not occur when rats were pretreated with naloxone (2 mg/kg, IP). The rats receiving saline did not show any behavioral changes throughout the 2 hour period of observation. ?-CM7 also demonstrated analgesic effects, which could be blocked by naloxone. The results suggest that ?-CM7 may play a role in behavioral disorders such as autism and schizophrenia. En ligne : http://dx.doi.org/10.1177/1362361399003001007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=208
in Autism > 3-1 (March 1999) . - p.85-95[article] A Peptide Found in Schizophrenia and Autism Causes Behavioral Changes in Rats [Texte imprimé et/ou numérique] / Zhongjie SUN, Auteur ; J. Robert CADE, Auteur . - p.85-95.
Langues : Anglais (eng)
in Autism > 3-1 (March 1999) . - p.85-95
Index. décimale : PER Périodiques Résumé : In a previous study we showed that ?-casomorphin-7 (?-CM7) is taken up by brain regions relevant to schizophrenia and autism. The present experiment was designed to find whether ?-CM7 has any behavioral or analgesic effects in rats. About 65 seconds after treatment with different doses of ?-CM7, rats became restless and ran violently, with teeth chattering and with rapid respiration. Seven minutes later, the rats became inactive with less walking, distancing themselves from the other rat in the same cage, and sitting in, or putting their head against, the corner of the cage. The sound response was reduced and social interaction was absent. One hour later, the rats showed hyperdefensiveness. The above behavioral effects of ?-CM7 did not occur when rats were pretreated with naloxone (2 mg/kg, IP). The rats receiving saline did not show any behavioral changes throughout the 2 hour period of observation. ?-CM7 also demonstrated analgesic effects, which could be blocked by naloxone. The results suggest that ?-CM7 may play a role in behavioral disorders such as autism and schizophrenia. En ligne : http://dx.doi.org/10.1177/1362361399003001007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=208